Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-07

Study Completion Date

2019-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Rec 0/0438 in subjects with neurogenic detrusor overactivity due to spinal cord injury

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

NCT00800462

Spinal Cord Injury Neurogenic Detrusor Overactivity

COMPLETED PHASE4

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029

Detrusor Hyperreflexia

COMPLETED PHASE4

Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients

NCT00332319

Incontinence, Urinary and Urinary Bladder, Overactive Overactive Bladder

TERMINATED PHASE2

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

NCT03817931

Overactive Bladder Dementia Lower Urinary Tract Symptoms +1 more

COMPLETED PHASE4

Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury

NCT03187795

Spinal Cord Injuries Urinary Bladder, Neurogenic

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Multicentre, double-blind, randomised, parallel groups, placebo-controlled study to be conducted in specialized centres in Europe to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of two different doses of Rec 0/0438 in comparison with placebo, in subjects with neurogenic detrusor overactivity due to spinal cord injury.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurogenic Detrusor Overactivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

two sequential cohorts, each corresponding to a dose level.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rec 0/0438

Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks

Group Type EXPERIMENTAL

Rec 0/0438 1 mg or Rec 0/0438 2 mg

Intervention Type DRUG

Each vial content will be administered via the catheter used for the self-catheterization

Placebo

Placebo, to be administered by intravesical instillation once daily for four weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Each vial content will be administered via the catheter used for the self-catheterization

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rec 0/0438 1 mg or Rec 0/0438 2 mg

Each vial content will be administered via the catheter used for the self-catheterization

Intervention Type DRUG

placebo

Each vial content will be administered via the catheter used for the self-catheterization

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects aged ≥18 years and ≤65 years.
* Female subjects must be either sterile or, if with child-bearing potential, must have a pregnancy test negative and commit to the use of a highly effective method of birth control (see Appendix 15.6) for the duration of the study, and until at least 1 month after the last dose of study medication. Male subjects must be willing to use male contraception (condom) to avoid pregnancies of their female partner of childbearing potential throughout the entire duration of the study, and for 3 months after the last dose of study medication.
* Suffering from NDO due to SCI at upper motor neuron level (below C6) and emptying the bladder performing clear intermittent self-catheterization (CISC).
* Subjects classified in group A, B, or C, of the ASIA (American Spinal Injury Association) impairment scale.
* Stable therapy for NDO in the last thirty days (Subjects should maintain the therapy stable for the duration of the study).
* At least 1 incontinence episode/day despite current treatment, according to what is reported in the Bladder Diary filled in by the subject.
* Subjects with diastolic blood pressure values between 60 and 99 mmHg (both inclusive), and systolic blood pressure values between 90 and 159 mmHg (both inclusive). Blood pressure measurement must be performed in subjects with an empty bladder.
* Subjects with stable concomitant medication treatment at baseline.
* Written informed consent must be given by subjects before any study related investigational procedures is performed.

Exclusion Criteria

* Breastfeeding women.
* Treatment with injection of botulinum toxin, unless in the opinion of the Investigator the bladder activity has returned to pre-treatment level.
* Use of prohibited concomitant medications, such as drugs that could affect immunoassay testing (systemic corticosteroids: prednisone, budesonide, prednisolone; calcineurin inhibitors: cyclosporine, tacrolimus; mTOR inhibitors: sirolimus, everolimus; IMDH inhibitors: azathioprine, leflunomide, mycophenolate; biologics: abatacept, adalimumab, anakinra , certolizumab, etanercept, golimumab, infliximab, ixekizumab, natalizumab, rituximab, secukinumab, tocilizumab, ustekinumab, vedolizumab; monoclonal antibodies: basiliximab, daclizumab, muromonab) or initiation of therapy with drugs affecting lower urinary tract symptoms (such as alpha-blockers, tadalafil 5 mg oad). If already present at Screening visit, therapy with drugs affecting lower urinary tract symptoms must be maintained stable through the study period (Note: occasional treatment with PDE-5 inhibitors for erectile dysfunction should be avoided between Screening visit and Day 8 and between Day 25 and 28).
* History of cerebro- or cardio-vascular diseases (TIA, stroke, hypertensive encephalopathy, angina pectoris, MI, cardiac by-pass, CHF NYHA classes III and IV).
* Uncontrolled type 1 or type 2 diabetes (Hb A1c \>8 %).
* Moderate to severe renal impairment (estimated creatinine clearance \<60 mL/min by the Cockcroft-Gault equation).
* Moderate to severe liver impairment (any liver function test: AST, ALT, GGT, Bilirubin \>2.5 times the upper limit of normal).
* Hemodynamically significant valve disease, including aortic stenosis or clinically significant ventricular or supraventricular arrhythmia, heart rate \>100 beats/min.
* Clinically important abnormal laboratory findings during the run-in period, including: Haemoglobin \<10 g/dL; Serum Potassium \>5.5 mmol/L; Serum Sodium \<132 mmol/L.
* Symptomatic active urinary tract infection (i.e. cloudy and/or malodorous urine, chills, fever, increased muscle spasticity or increased autonomic dysreflexia, letargy, hypotension, malaise).
* Evidence of any neoplastic disease.
* History of allergy, hypersensitivity or intolerance to drugs.
* Participation in an investigational drug study within 30 days prior to the screening assessment.
* Any other diseases or conditions, that according to the Investigator's opinion, make the subject unable to comply with protocol requirements, or unable to complete the study or increases the risk to the subject or which prevents optimal participation in achieving the objectives of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No